ArticleJournal of neuropathology and experimental neurology2023

Validating MCM2 as a clinically relevant surrogate immunohistochemical marker for an aggressive meningioma molecular subtype.

Allison Shelbourn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.